| ¿µ¹® | reserve cell | ÇÑ±Û | ¿¹ºñ¼¼Æ÷ |
|---|---|---|---|
| ¼³¸í | ÀϹÝÀûÀ¸·Î »óÇÇÁ¶Á÷¿¡¼ ÀÌ¹Ì ÀÖ´ø »óÇǼ¼Æ÷°¡ ¼Õ»óÀ» ¹Þ¾Æ »ç¸êÇÏ¸é ¸Å²ãÁö´Â ±× ¹Ø¿¡ ÀÖ´Â ¹ÌºÐȼ¼Æ÷ ¿¹¸¦ µé¸é, ±â°üÁö ³»Ç¥¸éÀ» µ¤´Â ÁßÃþ ¿øÁÖ »óÇÇÀÇ ±âÀú¿¡ ÀÖ´Â ÀÛÀº ¹ÌºÐÈ »óÇÇ ¼¼Æ÷. |
||
| ¿µ¹® | stem cell | ÇÑ±Û | Áٱ⼼Æ÷, °£¼¼Æ÷ |
|---|---|---|---|
| ¼³¸í | Àڱ⠺¹Á¦¸¦ ÇÏ¿© ÀÚ½ÅÀ» Á¸¼Ó½ÃŰ¸é¼ ÇÑÆíÀ¸·Î´Â Áõ½Ä°ú ºÐȸ¦ ÇÏ¿© »õ·Î¿î ¼¼Æ÷¸¦ Çü¼ºÇÏ´Â ¼¼Æ÷·Î¼ Á¶Ç÷Áٱ⼼Æ÷°¡ ´ëÇ¥ÀûÀÌ´Ù. Á¶Ç÷Áٱ⼼Æ÷´Â °ñ¼ö¿¡ ÀÖ´Â ¼¼Æ÷·Î¼ ¸ðµç Ç÷±¸¼¼Æ÷°¡ ¿©±â¿¡¼ ºÐÈµÇ¾î ¹ß»ýÇÑ´Ù. |
||
| ¿µ¹® | renal cell carcinoma | ÇÑ±Û | ÄáÆÏ¼¼Æ÷¾ÏÁ¾ |
|---|---|---|---|
| ¼³¸í | ÄáÆÏ¿¡ »ý±ä ¿ø½ÃÄáÆÏÁ¶Á÷¿¡¼ ¹ß»ýÇÑ ¾Ï. ÁÖ·Î ¿ø½Ã¼¼´¢°üÁ¶Á÷¿¡¼ ¹ß»ýÇÑ´Ù. ´ëÇ¥ÀûÀÎ ¼¼Æ÷Á¶Á÷ÇüÀº ¿°»ö½Ã ¼¼Æ÷ÁúÀÌ ¸¼°Ô ºñ¾îº¸ÀÌ´Â ¸¼Àº¼¼Æ÷¾ÏÁ¾ÀÌ´Ù. Ä¡·á´Â ¼ö¼ú°ú Ç×¾ÏÈÇпä¹ýÀÌ¸ç ¾ÆÁÖ µå¹°Áö¸¸ ÀúÀý·Î ³´´Â °æ¿ìµµ ÀÖ´Â °ÍÀ¸·Î º¸°íµÇ¾î ÀÖ´Ù. |
||
| ¿µ¹® | squamous cell carcinoma | ÇÑ±Û | ÆíÆò¼¼Æ÷¾ÏÁ¾ |
|---|---|---|---|
| ¼³¸í | ÆíÆò¼¼Æ÷ ±â¿øÀÇ ¾ÏÀ¸·Î¼, ÆíÆò¼¼Æ÷°¡ ÀÖ´Â ¾î¶² °÷¿¡¼µç ¹ß»ý°¡´ÉÇÔ. µû¶ó¼ ½Äµµ¾Ï, ÇǺξÏ, Æó¾Ï, ÀÚ±Ã¾Ï µîÀÌ ¿©±â¿¡ ÇØ´çµÈ´Ù. ƯÈ÷ ÇǺξÏÀº ¸¹Àº Àڿܼ±Á¶»ç¿¡ ÀÇÇØ »ý±â´Â ±¤¼±°¢ÈÁõ¿¡¼ ¹ß»ý°¡´ÉÇÏ´Ù. º´¸®Á¶Á÷ÇÐÀû Ư¼ºÀ¸·Î¼ °¢ÁúÀ» »ý¼ºÇÑ´Ù. |
||
| TF | free thyroxine; tactile fremitus; tail flick [reflex]; temperature factor; testicular feminization; ... |
|---|---|
| GB | gallbladder; glial bundle; goof balls; Guillain-Barre [syndrome] |
| GFA | glial fibrillary acidic [protein] |
| GFAP | glial fibrillary acidic protein |
| NT | nasotracheal; neotetrazolium; neurotensin; neurotrophic; neutralization test; nicotine tartrate; non... |
| receptors, antigen, T-cell, gamma-delta | T-cell receptors composed of CD3-associated gamma and delta polypeptide chains and expressed primarily in CD4-/CD8- T-cells. The receptors appear to be preferentially located in epithelial sites and probably play a role in the recognition of bacterial antigens. The T-cell receptor gamma/delta chains are separate and not related to the gamma and delta chains which are subunits of CD3 (see antigens, CD3). (12 Dec 1998) |
|---|---|
| receptors, cell surface | Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behaviour of the target cell. Cell surface receptors, unlike enzymes, do not chemically alter their ligands. (12 Dec 1998) |
| T-cell antigen receptors | Receptors present on T-cells that interact with both processed antigen and major histocompatibility antigens simultaneously. (05 Mar 2000) |
| B-cell differentiating factor | <cytokine> A soluble cytokine factor produced by activated T-lymphocytes that promotes antibody production by causing proliferation and differentiation of B-cells. Interleukin-4 induces the expression of class II major histocompatibility complex and fc receptors on B-cells. It also acts on T-lymphocytes, mast cell lines, and several other haematopoietic lineage cells including granulocyte, megakaryocyte, and erythroid precursors, as well as macrophages. Acronym: IL-4 (12 Dec 1998) |
| B-cell stimulatory factor 2 | <cytokine> A cytokine that stimulates the growth and differentiation of human B-cells and is also a growth factor for hybridomas and plasmacytomas. It is produced by many different cells including T-cells, monocytes, and fibroblasts. A single chain 25 kD cytokine originally described as a pre B-cell growth factor, now known to have effects on a number of other cells including T-cells which are also stimulated to proliferate. An inducer of acute phase proteins and a colony-stimulating factor acting on mouse bone marrow. Acronym: IL-6 (12 Dec 1998) |
| natural killer cell stimulating factor | <cytokine> A 75 kD heterodimeric cytokine composed of disulfide-bonded 40 kD and 35 kD subunits that was originally identified by its ability to induce cytotoxic effector cells in synergy with less than optimal concentrations of interleukin-2. It is released by macrophages in response to infection and promotes the activation of cell-mediated immunity. Specifically, IL-12 triggers the maturation of Thl CD4 cells, specific cytotoxic T-lymphocyte responses and an increase in the activity of NK cells and consequently, it is the initiator of cell-mediated immunity. It enhances the lytic activity of NK cells, induces interferon production, stimulates the proliferation of activated T-cells and NK cells. Is secreted by human B lymphoblastoid cells (NC 37). May play a role in controlling immunoglobulin isotype selection as it also inhibits IgE synthesis (even in the presence of anti-IFN monoclonal antibody) and as a growth factor for activated CD4+ and CD8+ T-cells independently of interleukin-2, and for CD56+ NK cells but not resting peripheral blood mononuclear cells or resting or activated tonsillar B-cells. It is likely that interleukin 12 has a major role in protective immunity against viruses and is under study as an immunotherapy in HIV infection. Formerly referred to as cytotoxic lymphocyte maturation factor. Acronym: IL-12 (12 Dec 1998) |
| stem cell factor | <growth factor> Haemopoietic growth factor 18.6 kD from sequence, found as dimer (35 kD protein, 53 kD in its glycosylated form). Acronym: SCF (18 Nov 1997) |
| T-cell growth factor | <cytokine> A hormone-like substance released by stimulated T lymphocytes, causes activation and differentiation of other T lymphocytes independently of antigen. A type of interleukin, a chemical messenger, a substance that can improve the body's response to disease. It stimulates the growth of certain disease-fighting blood cells in the immune system. It is secreted by Thl CD4 cells to stimulate CD8 cytotoxic T-1yrnphocytes. Interleukin 2 also increases the proliferation and maturation of the CD4 cells themselves. During HIV infection, Interleukin-2 production gradually declines. Use of interleukin 2 therapy is under study as a way to raise CD4 cell counts and restore immune function. Acronym: IL-2 (12 Dec 1998) |
| T-cell growth factor-1 | <cytokine> A hormone-like substance released by stimulated T lymphocytes, causes activation and differentiation of other T lymphocytes independently of antigen. A type of interleukin, a chemical messenger, a substance that can improve the body's response to disease. It stimulates the growth of certain disease-fighting blood cells in the immune system. It is secreted by Thl CD4 cells to stimulate CD8 cytotoxic T-1yrnphocytes. Interleukin 2 also increases the proliferation and maturation of the CD4 cells themselves. During HIV infection, Interleukin-2 production gradually declines. Use of interleukin 2 therapy is under study as a way to raise CD4 cell counts and restore immune function. Acronym: IL-2 (12 Dec 1998) |
| T-cell growth factor-2 | <cytokine> A soluble cytokine factor produced by activated T-lymphocytes that promotes antibody production by causing proliferation and differentiation of B-cells. Interleukin-4 induces the expression of class II major histocompatibility complex and fc receptors on B-cells. It also acts on T-lymphocytes, mast cell lines, and several other haematopoietic lineage cells including granulocyte, megakaryocyte, and erythroid precursors, as well as macrophages. Acronym: IL-4 (12 Dec 1998) |
| T-cell-rich, B-cell lymphoma | <tumour> A B-cell lymphoma in which more than 90% of the cells are of T-cell origin, masking the large cells that form the neoplastic B-cell component. See: adult T-cell lymphoma. (05 Mar 2000) |
| adrenergic receptors | Reactive components of effector tissues, most of which are innervated by adrenergic postganglionic fibres of the sympathetic nervous system. Such receptor's can be activated by norepinephrine and/or epinephrine and by various adrenergic drugs; receptor activation results in a change in effector tissue function, such as contraction of arteriolar muscles or relaxation of bronchial muscles; adrenergic receptor's are divided into alpha-receptor's and beta-receptor's, on the basis of their response to various adrenergic activating and blocking agents. Synonym: adrenoceptor, adrenoreceptors. (05 Mar 2000) |
| alpha-adrenergic receptors | Adrenergic receptor's in effector tissues capable of selective activation and blockade by drugs; conceptually derived from the ability of certain agents, such as phenoxybenzamine, to block only some adrenergic receptor's and of other agents, such as methoxamine, to activate only the same adrenergic receptor's. Such receptor's are designated as alpha-receptors. Their activation results in physiological responses such as increased peripheral vascular resistance, mydriasis, and contraction of pilomotor muscles. (05 Mar 2000) |
| ANP clearance receptors | Cell surface proteins that bind atrial natriuretic peptide and ANP fragments without initiating biological action. (05 Mar 2000) |
| ANP receptors | Cell surface receptors for atrial natriuretic peptide that have a single transmembrane spanning element; these have integral kinase and guanylate cyclase domains. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|